ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 954

Physical Therapy and Opioid Use in Knee Osteoarthritis

Deepak Kumar1, Christine Peloquin 2, Andrew Stokes 3, Lee Marinko 4, James Camarinos 4, David Felson 5 and Maureen Dubreuil 2, 1Boston University, Boston, MA, 2Boston University School of Medicine, Boston, 3Boston University School of Public Health, Boston, 4Boston University, Boston, 5Boston University School of Medicine, Department of Rheumatology, Boston

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: opioids, osteoarthritis and Knee, physical therapy

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: 3S089: Health Services Research I: Clinical Perspectives (951–956)

Session Type: ACR/ARP Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Knee osteoarthritis (OA) is a leading cause of chronic pain in older adults.  Physical therapy (PT) decreases OA pain and consequently may reduce burden of opioid use in this population. The purpose of this study was to investigate the associations of type, dose, and timing of PT with utilization of opioids following PT in individuals with incident knee OA who had used opioids in the past or were opioid naïve, using data from a large claims database.

Methods: We conducted a cohort study using 2000-2014 data from the OptumLabs® Data Warehouse (OLDW), a longitudinal, real-world dataset with de-identified administrative claims and electronic health record (EHR) data. We included adults between the ages of 40-89, who after ≥ 6 months of claims data, had a knee OA diagnosis using ICD9 codes, the date of which we defined as the index date. We excluded individuals with OA-related surgeries, knee injuries, PT, cancer, or rheumatoid arthritis within 6 months prior to index date. Only persons who received PT within 12 months of the index date and who had at least 1 year of follow-up after the first PT episode of care were included. The first PT episode of care was considered to start with an initial PT evaluation followed by at least one treatment session, and was considered to end if there was a 4-week period with no PT claim or if a second evaluation was recorded. We studied several PT exposures including dose (number of sessions), timing and active versus passive modality (Table 1). The outcome was any opioid use in the 12 months after the end of the PT episode of care. Opioid use was defined as at least 2 filled prescriptions of opioids commonly used for musculoskeletal pain. Combinations of opioids with medications commonly used for cough, nasal congestion, and headache were excluded. We conducted the analyses in individuals who had used opioids prior to PT (“opioid experienced”) and those who had not used opioids prior to PT (“opioid naïve”). Covariates included age, hyperlipidemia, diabetes, and overweight/obesity. Adjusted odds (aOR) of receiving opioids were assessed  (Table 1) using logistic regression.

Results: We included 32,324 opioid experienced (age=60.9±10.3 years; 61.5% female) and 39,302 opioid naïve individuals (age=62.6±11.2 years; 66.0% female) (Table 2). Among both opioid experienced and opioid naïve individuals, more than 5 sessions of PT and early PT after knee OA diagnosis (vs. > 6 months) were associated with reduced odds of opioid use (Table 2, Figure 1). Among opioid naïve individuals, receiving PT >3 months after diagnosis vs. earlier was related with increase odds of opioid use (Table 2, Figure 1).  Receiving active PT (vs. passive PT) was associated with reduced odds of further opioid use in opioid experienced individuals but not in the opioid naïve group (Table 2, Figure 1).

Conclusion: PT provided earlier after OA diagnosis, more than 5 sessions of PT, and use of active PT interventions may reduce opioid use in people with knee OA. These results provide guidance on optimal dosage, timing, and type of PT interventions that might be effective at reducing opioid use in this population.

Table 1. Exposure definitions

Table 2. Prevalence of exposure and outcomes among opioid experienced and naïve individuals

Figure 1. Adjusted odds ratios of opioid use among opioid experienced and naïve individuals


Disclosure: D. Kumar, None; C. Peloquin, None; A. Stokes, None; L. Marinko, None; J. Camarinos, None; D. Felson, None; M. Dubreuil, None.

To cite this abstract in AMA style:

Kumar D, Peloquin C, Stokes A, Marinko L, Camarinos J, Felson D, Dubreuil M. Physical Therapy and Opioid Use in Knee Osteoarthritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/physical-therapy-and-opioid-use-in-knee-osteoarthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/physical-therapy-and-opioid-use-in-knee-osteoarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology